TipRanks
Go Ultimate55% OFF

Paxman AB (PAX) Stock Price & Analysis

PAX Stock Chart & Stats

SEK 63.80-SEK 2.50(-3.77%)
At close: 5:24 PM GMT+1
kr 50kr 6010 Aug24 Aug7 Sep21 Sep5 Oct19 Oct2 Nov
Day’s Range
SEK 63.00 - SEK 67.90
52-Week Range
SEK 41.00 - SEK 69.90
Previous Close
SEK 66.30
Volume
N/A
Average Volume (3M)
17.96K
Market Cap
SEK 1.54B
Enterprise Value
SEK 1.06B
Total Cash (Recent Filing)
SEK 105.64M
Total Debt (Recent Filing)
SEK 12.37M
Price to Earnings (P/E)
―
Beta
0.16
Next Earnings
Nov 20, 2026 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Commercial Momentum

Rapid sales growth and a substantial order book indicate expanding demand for Paxman’s scalp-cooling systems. This supports continued site expansion and future equipment revenue, while strengthening the installed base that can generate ongoing usage and service income.

IBBM Utilization Growth

Insurance-based billing is increasing treatment utilization and recurring cap revenue, addressing a key adoption barrier for patients and clinics. Higher usage per site and system can improve the economics of the installed base and make customer relationships more valuable over time.

Conservative Financing

Very low leverage limits interest and refinancing pressure, giving Paxman greater flexibility to fund commercial expansion, product development, and integration initiatives. A conservatively financed balance sheet also provides more resilience while profitability and cash generation are being rebuilt.

Bears Say

Negative Cash Generation

Negative operating and free cash flow means current operations and investment are not being funded internally. If this persists, Paxman may need to rely more heavily on existing liquidity or external funding, reducing flexibility for expansion and increasing financial execution risk.

Profitability Pressure

The shift from prior profitability to a TTM loss, alongside near-break-even EBIT and lower gross margin, raises questions about earnings durability. Cost or mix pressure could limit operating leverage, making strong revenue growth less effective at translating into sustainable profits.

Neuropathy Regulatory Delay

The De Novo requirement delays the neuropathy device and introduces greater approval uncertainty than the planned 510(k) route. Potential additional data requests could extend the timeline further, postponing related revenue and increasing the cost of reaching commercialization.

Paxman AB News

PAX FAQ

What was Paxman AB’s price range in the past 12 months?
Paxman AB lowest stock price was kr 41.00 and its highest was kr 69.90 in the past 12 months.
What is Paxman AB’s market cap?
Paxman AB’s market cap is kr 1.54B.
When is Paxman AB’s upcoming earnings report date?
Paxman AB’s next earnings report is estimated for Nov 20, 2026 (not yet confirmed), which is in 17 days.
How were Paxman AB’s earnings last quarter?
Paxman AB released its earnings results on Aug 21, 2026. The company reported kr 0.1 earnings per share for the quarter, missing the consensus estimate of kr 0.3 by -kr 0.2.
Is Paxman AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Paxman AB pay dividends?
Paxman AB does not currently pay dividends.
What is Paxman AB’s EPS estimate?
Paxman AB’s EPS estimate is 0.40.
How many shares outstanding does Paxman AB have?
Paxman AB has 23,273,417 shares outstanding.
What happened to Paxman AB’s price movement after its last earnings report?
Paxman AB reported an EPS of kr 0.1 in its last earnings report, missing expectations of kr 0.3. Following the earnings report the stock price went up 17.271%.
Which hedge fund is a major shareholder of Paxman AB?
Currently, no hedge funds are holding shares in SE:PAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology